Collegium Pharmaceutical, Inc. (COLL) vs Design Therapeutics, Inc. (DSGN)
A side-by-side comparison of Collegium Pharmaceutical, Inc. and Design Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
COLL
Collegium Pharmaceutical, Inc.
$21.97HealthcareDelayed quote: Oct 6, 2026, 2:45 PM EDT
DSGN
Design Therapeutics, Inc.
$11.93HealthcareDelayed quote: Oct 6, 2026, 2:44 PM EDT
Total return — COLL vs DSGN
growth of $100 · dividends reinvested · last 6yCOLL -8.1% (-1.4%/yr)DSGN -70.1% (-18.2%/yr)COLL compounded faster over this window
COLL DSGN
COLL vs DSGN: by the numbers
- •DSGN is the larger company ($745M vs $713M market cap).
- •COLL is profitable (5.93% net margin) while DSGN runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | COLL | DSGN |
|---|---|---|
| P/E ratio | 17.72 | N/A |
| PEG ratio | 0.99 | N/A |
| P/S ratio | 0.88 | N/A |
| P/B ratio | 2.28 | 3.69 |
| EV / EBITDA | 2.85 | N/A |
| FCF yield | 46.06% | N/A |
Profitability
| Metric | COLL | DSGN |
|---|---|---|
| Gross margin | 60.02% | 0.00% |
| Operating margin | 19.61% | 0.00% |
| Net margin | 5.93% | 0.00% |
| ROE | 15.36% | -35.07% |
| ROIC | 6.11% | -38.92% |
Growth (annualized)
| Metric | COLL | DSGN |
|---|---|---|
| Revenue CAGR (5Y) | 19.91% | N/A |
| EPS CAGR (5Y) | 20.48% | N/A |
| FCF CAGR (5Y) | 26.38% | N/A |
| Total return CAGR (5Y) | 2.15% | -3.82% |
Frequently asked
- Is COLL or DSGN more profitable?
- COLL runs the higher net margin — COLL at 5.93% versus DSGN at 0.00%.
- How have COLL and DSGN total returns compared?
- Over the past 5 years, COLL delivered 2.15% and DSGN delivered -3.82% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Collegium Pharmaceutical P/E ratioCollegium Pharmaceutical ROEDesign Therapeutics ROECollegium Pharmaceutical operating marginDesign Therapeutics operating marginCollegium Pharmaceutical revenue growthDesign Therapeutics revenue growthCollegium Pharmaceutical free cash flowDesign Therapeutics free cash flow
Collegium Pharmaceutical & Design Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.